Clinical Trial Update: Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating neoadjuvant tumor-infiltrating lymphocyte (TIL)– and response-adapted chemoimmunotherapy for triple-negative breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TIL therapy (tumor-infiltrating lymphocytes) (tumor-infiltrating lymphocytes (TIL) therapy)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Triple Negative Breast Cancer, Breast Cancer | Phase 2 | Status: RECRUITING